{"id":142824,"date":"2026-07-08T12:07:45","date_gmt":"2026-07-08T06:37:45","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=142824"},"modified":"2026-07-08T12:07:46","modified_gmt":"2026-07-08T06:37:46","slug":"beta-drugs-q1-results-2027-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/beta-drugs-q1-results-2027-preview\/","title":{"rendered":"Beta Drugs Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target"},"content":{"rendered":"
<\/div>\n

Beta Drugs CMP Rs.2,075. Market cap Rs.2,183 Cr. PE Not meaningful. 12-month target Rs.2,096-2,366.<\/em><\/p>\n

Beta Drugs<\/a> Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Beta Drugs shares trading at Rs.2,075 against a market capitalisation of Rs.2,183 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Beta Drugs enters the Beta Drugs Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.<\/p>\n

Quarterly financials for Beta Drugs are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE\/BSE filings directly for the Beta Drugs Q1 Results FY27 result date and cross-check any figures before making investment decisions.<\/p>\n

Get Free Investment Predictions and Beta Drugs Research at Univest<\/strong><\/a><\/p>\n

Beta Drugs (NSE: BETA) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Beta Drugs Q1 Results FY27 season, forming the base against which the Beta Drugs Q1 Results FY27 estimates in this article are built. This Beta Drugs Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n